KDR and renal cell carcinoma: However, considering the pharmacologic mechanism of sunitinib, which mainly targets the VEGFR of the endothelial cells constructing the vessels around RCC solid tumors, the in vitro induced sunitinib resistance in RCC cells has weak clinical relevance.